RT Journal Article
SR Electronic
T1 The Invasive Respiratory Infection Surveillance (IRIS) Initiative reveals significant reductions in invasive bacterial infections during the COVID-19 pandemic
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.18.20225029
DO 10.1101/2020.11.18.20225029
A1 Angela B Brueggemann
A1 Melissa J Jansen van Rensburg
A1 David Shaw
A1 Noel McCarthy
A1 Keith A Jolley
A1 Martin CJ Maiden
A1 Mark PG van der Linden
A1 Zahin Amin-Chowdhury
A1 Désirée E Bennett
A1 Ray Borrow
A1 Maria-Cristina C Brandileone
A1 Karen Broughton
A1 Ruth Campbell
A1 Bin Cao
A1 Carlo Casanova
A1 Eun Hwa Choi
A1 Yiu Wai Chu
A1 Stephen A Clark
A1 Heike Claus
A1 Juliana Coelho
A1 Mary Corcoran
A1 Simon Cottrell
A1 Robert J Cunney
A1 Tine Dalby
A1 Heather Davies
A1 Linda de Gouveia
A1 Ala-Eddine Deghmane
A1 Walter Demczuk
A1 Stefanie Desmet
A1 Richard J Drew
A1 Mignon du Plessis
A1 Helga Erlendsdottir
A1 Norman K Fry
A1 Kurt Fuursted
A1 Steve J Gray
A1 Birgitta Henriques-Normark
A1 Thomas Hale
A1 Markus Hilty
A1 Steen Hoffmann
A1 Hilary Humphreys
A1 Margaret Ip
A1 Susanne Jacobsson
A1 Jillian Johnston
A1 Jana Kozakova
A1 Karl G Kristinsson
A1 Pavla Krizova
A1 Alicja Kuch
A1 Shamez N Ladhani
A1 Thiên-Trí Lâm
A1 Vera Lebedova
A1 Laura Lindholm
A1 David Litt
A1 Irene Martin
A1 Delphine Martiny
A1 Wesley Mattheus
A1 Martha McElligott
A1 Mary Meehan
A1 Susan Meiring
A1 Paula Mölling
A1 Eva Morfeldt
A1 Julie Morgan
A1 Robert M Mulhall
A1 Carmen Muñoz-Almagro
A1 David R Murdoch
A1 Joy Murphy
A1 Martin Musilek
A1 Alexandre Mzabi
A1 Amaresh Perez-Argüello
A1 Monique Perrin
A1 Malorie Perry
A1 Alba Redin
A1 Richard Roberts
A1 Maria Roberts
A1 Assaf Rokney
A1 Merav Ron
A1 Kevin Scott
A1 Carmen L. Sheppard
A1 Lotta Siira
A1 Anna Skoczyńska
A1 Monica Sloan
A1 Hans-Christian Slotved
A1 Andrew J Smith
A1 Joon Young Song
A1 Muhamed-Kheir Taha
A1 Maija Toropainen
A1 Dominic Tsang
A1 Anni Vainio
A1 Nina M van Sorge
A1 Emmanuelle Varon
A1 Jiri Vlach
A1 Ulrich Vogel
A1 Sandra Vohrnova
A1 Anne von Gottberg
A1 Rosemeire C Zanella
A1 Fei Zhou
YR 2020
UL http://medrxiv.org/content/early/2020/11/20/2020.11.18.20225029.abstract
AB Background Streptococcus pneumoniae, Haemophilus influenzae and Neisseria meningitidis are leading causes of invasive diseases including bacteraemic pneumonia and meningitis, and of secondary infections post-viral respiratory disease. They are typically transmitted via respiratory droplets. We investigated rates of invasive disease due to these pathogens during the early phase of the COVID-19 pandemic.Methods Laboratories in 26 countries across six continents submitted data on cases of invasive disease due to S pneumoniae, H influenzae and N meningitidis from 1 January 2018 to 31 May 2020. Weekly cases in 2020 vs 2018-2019 were compared. Streptococcus agalactiae data were collected from nine laboratories for comparison to a non-respiratory pathogen. The stringency of COVID-19 containment measures was quantified by the Oxford COVID-19 Government Response Tracker. Changes in population movements were assessed by Google COVID-19 Community Mobility Reports. Interrupted time series modelling quantified changes in rates of invasive disease in 2020 relative to when containment measures were imposed.Findings All countries experienced a significant, sustained reduction in invasive diseases due to S pneumoniae, H influenzae and N meningitidis, but not S agalactiae, in early 2020, which coincided with the introduction of COVID-19 containment measures in each country. Similar impacts were observed across most countries despite differing stringency in COVID-19 control policies. There was no evidence of a specific effect due to enforced school closures.Interpretation The introduction of COVID-19 containment policies and public information campaigns likely reduced transmission of these bacterial respiratory pathogens, leading to a significant reduction in life-threatening invasive diseases in many countries worldwide.Competing Interest StatementThe German Reference Center for Streptococci receives financial support from Pfizer and Merck. MC has previously received a professional fee from Pfizer (Ireland), an unrestricted research grant from Pfizer Ireland (2007-2016) and an Investigator Initiated Reward from Pfizer Ireland in 2018 (W1243730). HH has received research funds from Astellas and Pfizer and a professional fee from Pfizer. The funders had no role in the collection, analysis, interpretation of data or in the writing of and decision to submit the article for publication.Funding StatementThe infrastructure for the IRIS initiative was funded by a Wellcome Trust Investigator Award to ABB (grant number 206394/Z/17/Z) and a Wellcome Trust Biomedical Resource Grant to MJCM, ABB and KAJ (grant number 218205/Z/19/Z). The German National Reference Laboratory for Meningococci and Haemophilus influenzae is supported by the Robert Koch Institute with funds from the Federal Ministry of Health (funding code 1369-237). The Irish Meningitis and Sepsis Reference Laboratory has received support from Childrens Health Ireland at Temple Street, the Royal College of Surgeons in Ireland, Health Protection Surveillance Centre and the SpID-Net project, which has received funding from the European Centre for Disease Prevention and Control (ECDC) and Horizon 2020. The Polish data collection was partially supported by the Ministry of Health within the framework of the National Programme of Antibiotic Protection (NPOA) and by the Ministry of Science and Higher Education (Mikrobank 2 Programme). Funding for materials, equipment and human resources associated with the laboratory in Catalonia, Spain was provided by Agencia de Salut Publica de Catalunya and Sant Joan de Deu Foundation. BHN has received funding from the Knut and Alice Wallenberg Foundation, the Swedish Research Council and Region Stockholm. The funders had no role in the collection, analysis, interpretation of data or in the writing of and decision to submit the article for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Prof Kevin Marsh is the chair of OxTREC, the University of Oxford ethical committee that considers health related research conducted by Oxford-associated researchers where the research is primarily conducted outside of the UK. He confirmed that OxTREC would not require this study to go through ethical review, because it involves routine surveillance and no possibility of individual patients being identified. Prof Marsh also stated that this is the view that is taken by other ethical committees that he is familiar with. https://researchsupport.admin.ox.ac.uk/governance/ethics/committees/oxtrecAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesA list of anonymised cases with sampling dates is available upon request. OxCGRT data are publicly available and found here: https://covidtracker.bsg.ox.ac.uk/ Google Mobility Reports data are publicly available and found here: https://www.google.com/covid19/mobility/